托法替布治疗强直性脊柱炎:III期随机双盲安慰剂对照研究
这项III期随机双盲安慰剂对照研究纳入269例活动性强直性脊柱炎成人患者,评估托法替布5mg每日两次的疗效与安全性。第16周托法替布组ASAS20和ASAS40应答率均显著高于安慰剂组,安全性未见新的潜在风险。
要点
- 托法替布5mg每日两次治疗活动性强直性脊柱炎,第16周ASAS20和ASAS40应答率显著优于安慰剂。
- 截至第48周,托法替布组报告了肝脏事件、非严重带状疱疹和严重感染,未出现死亡、恶性肿瘤、主要心血管不良事件、血栓栓塞事件或机会性感染。
- 该研究为托法替布用于活动性强直性脊柱炎提供了III期随机对照证据。
核心结论
- 在活动性强直性脊柱炎成人患者中,托法替布5mg每日两次的疗效显著优于安慰剂。
- 未发现新的潜在安全风险。
研究设计与样本
- III期随机双盲安慰剂对照研究,纳入年龄≥18岁、符合改良纽约标准、中心判读放射学结果、且对≥2种非甾体抗炎药应答不足或不耐受的活动性强直性脊柱炎患者。
- 患者按1:1随机接受托法替布5mg每日两次或安慰剂治疗16周,第16周后所有患者接受开放标签托法替布至第48周。
- 共269例患者随机并接受治疗:托法替布组n=133,安慰剂组n=136。
- 主要终点为第16周ASAS20应答率,关键次要终点为第16周ASAS40应答率。
主要发现
- 第16周托法替布组ASAS20应答率为56.4%(75/133),显著高于安慰剂组的29.4%(40/136),p<0.0001。
- 第16周托法替布组ASAS40应答率为40.6%(54/133),显著高于安慰剂组的12.5%(17/136),p<0.0001。
- 截至第16周,托法替布组和安慰剂组分别有54.9%(73/133)和51.5%(70/136)的患者发生不良事件,严重不良事件分别为1.5%(2/133)和0.7%(1/136)。
- 截至第48周,托法替布组有2.3%(3/133)患者发生裁定肝脏事件、2.3%(3/133)发生非严重带状疱疹、0.8%(1/133)发生严重感染;安慰剂转托法替布组有1.5%(2例)发生非严重带状疱疹。
- 截至第48周,未报告死亡、恶性肿瘤、主要心血管不良事件、血栓栓塞事件或机会性感染。
关键数值与推荐
- 主要终点第16周ASAS20应答率:托法替布56.4%(75/133)vs 安慰剂29.4%(40/136),p<0.0001。
- 关键次要终点第16周ASAS40应答率:托法替布40.6%(54/133)vs 安慰剂12.5%(17/136),p<0.0001。
- 入组要求:年龄≥18岁、符合改良纽约标准、中心判读放射学结果、对≥2种非甾体抗炎药应答不足或不耐受。
- 给药方案:托法替布5mg每日两次,对照安慰剂,双盲期16周,此后开放标签至第48周。
临床怎么用
- 对于对≥2种非甾体抗炎药应答不足或不耐受的活动性强直性脊柱炎成人患者,托法替布5mg每日两次可作为治疗选择之一。
- 治疗期间需关注不良事件,包括肝脏事件、带状疱疹和严重感染。
局限性
- 双盲安慰剂对照期仅16周,长期安全性数据来自开放标签延展期至第48周。
- 研究未报告其他潜在局限性信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess the efficacy/safety of tofacitinib in adult patients with active ankylosing spondylitis (AS). METHODS: This phase III, randomised, double-blind, placebo-controlled study enrolled patients aged ≥18 years diagnosed with active AS, meeting the modified New York criteria, with centrally read radiographs, and an inadequate response or intolerance to ≥2 non-steroidal anti-inflammatory drugs. Patients were randomised 1:1 to receive tofacitinib 5 mg two times per day or placebo for 16 weeks. After week 16, all patients received open-label tofacitinib until week 48. The primary and key secondary endpoints were Assessment of SpondyloArthritis international Society ≥20% improvement (ASAS20) and ≥40% improvement (ASAS40) responses, respectively, at week 16. Safety was assessed throughout. RESULTS: 269 patients were randomised and treated: tofacitinib, n=133; placebo, n=136. At week 16, the ASAS20 response rate was significantly (p<0.0001) greater with tofacitinib (56.4%, 75 of 133) versus placebo (29.4%, 40 of 136), and the ASAS40 response rate was significantly (p<0.0001) greater with tofacitinib (40.6%, 54 of 133) versus placebo (12.5%, 17 of 136). Up to week 16, with tofacitinib and placebo, respectively, 73 of 133 (54.9%) and 70 of 136 (51.5%) patients had adverse events; 2 of 133 (1.5%) and 1 of 136 (0.7%) had serious adverse events. Up to week 48, with tofacitinib, 3 of 133 (2.3%) patients had adjudicated hepatic events, 3 of 133 (2.3%) had non-serious herpes zoster, and 1 of 133 (0.8%) had a serious infection; with placebo→tofacitinib, 2 (1.5%) patients had non-serious herpes zoster. There were no deaths, malignancies, major adverse cardiovascular events, thromboembolic events or opportunistic infections. CONCLUSIONS: In adults with active AS, tofacitinib demonstrated significantly greater efficacy versus placebo. No new potential safety risks were identified. TRIAL REGISTRATION NUMBER: NCT03502616.
引用
- Deodhar A, Sliwinska-Stanczyk P, Xu H, et al. Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study. Ann Rheum Dis. 2021. PMID: 33906853. doi:10.1136/annrheumdis-2020-219601
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。